Comments
Loading...

Humacyte Analyst Ratings

HUMANASDAQ
Logo brought to you by Benzinga Data
$2.88
-0.44-13.40%
At close: -
$2.33
-0.54-18.96%
After Hours: 7:48 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$25.00
Lowest Price Target1
$3.00
Consensus Price Target1
$13.13

Humacyte Analyst Ratings and Price Targets | NASDAQ:HUMA | Benzinga

Humacyte Inc has a consensus price target of $13.13 based on the ratings of 9 analysts. The high is $25 issued by D. Boral Capital on March 7, 2025. The low is $3 issued by Piper Sandler on November 10, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., D. Boral Capital, and D. Boral Capital on March 12, 2025, March 7, 2025, and February 27, 2025, respectively. With an average price target of $21.67 between HC Wainwright & Co., D. Boral Capital, and D. Boral Capital, there's an implied 829.90% upside for Humacyte Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
3
Dec 24
2
Jan
3
Feb
2
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.8
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
D. Boral Capital
EF Hutton
TD Cowen
BTIG

1calculated from analyst ratings

Analyst Ratings for Humacyte

Buy NowGet Alert
03/12/2025Buy Now543.78%HC Wainwright & Co.
Vernon Bernardino52%
$15 → $15ReiteratesBuy → BuyGet Alert
03/07/2025Buy Now972.96%D. Boral Capital
Jason Kolbert48%
$25 → $25MaintainsBuyGet Alert
02/27/2025Buy NowBenchmark
Bruce Jackson42%
ReiteratesBuy → BuyGet Alert
02/27/2025Buy Now972.96%D. Boral Capital
Jason Kolbert48%
$25 → $25MaintainsBuyGet Alert
02/26/2025Buy Now972.96%D. Boral Capital
Jason Kolbert48%
$25 → $25MaintainsBuyGet Alert
01/21/2025Buy Now972.96%D. Boral Capital
Jason Kolbert48%
$25 → $25MaintainsBuyGet Alert
01/13/2025Buy Now972.96%D. Boral Capital
Jason Kolbert48%
$25 → $25MaintainsBuyGet Alert
12/23/2024Buy Now629.61%Benchmark
Bruce Jackson42%
$15 → $17MaintainsBuyGet Alert
12/20/2024Buy Now972.96%D. Boral Capital
Jason Kolbert48%
$25 → $25MaintainsBuyGet Alert
12/20/2024Buy Now543.78%HC Wainwright & Co.
Vernon Bernardino52%
$12 → $15ReiteratesBuy → BuyGet Alert
11/21/2024Buy Now972.96%D. Boral Capital
Jason Kolbert48%
$25 → $25MaintainsBuyGet Alert
11/18/2024Buy Now415.02%HC Wainwright & Co.
Vernon Bernardino52%
$12 → $12ReiteratesBuy → BuyGet Alert
11/13/2024Buy Now415.02%HC Wainwright & Co.
Vernon Bernardino52%
$12 → $12ReiteratesBuy → BuyGet Alert
11/11/2024Buy Now972.96%D. Boral Capital
Jason Kolbert48%
$25 → $25MaintainsBuyGet Alert
11/05/2024Buy Now415.02%HC Wainwright & Co.
Vernon Bernardino52%
$6 → $12MaintainsBuyGet Alert
10/28/2024Buy Now972.96%EF Hutton
Jason Kolbert48%
$25 → $25MaintainsBuyGet Alert
10/18/2024Buy Now329.18%TD Cowen
Joshua Jennings55%
$10 → $10ReiteratesBuy → BuyGet Alert
10/18/2024Buy Now329.18%BTIG
Ryan Zimmerman72%
$10 → $10ReiteratesBuy → BuyGet Alert
10/10/2024Buy Now543.78%Benchmark
Bruce Jackson42%
$15 → $15ReiteratesBuy → BuyGet Alert
10/01/2024Buy Now972.96%EF Hutton
Jason Kolbert48%
$25 → $25MaintainsBuyGet Alert
09/20/2024Buy Now457.94%Cantor Fitzgerald
Kristen Kluska70%
$13 → $13ReiteratesOverweight → OverweightGet Alert
09/09/2024Buy Now972.96%EF Hutton
Jason Kolbert48%
→ $25Initiates → BuyGet Alert
09/05/2024Buy Now543.78%Benchmark
Bruce Jackson42%
$15 → $15ReiteratesBuy → BuyGet Alert
08/14/2024Buy Now543.78%Benchmark
Bruce Jackson42%
$15 → $15ReiteratesBuy → BuyGet Alert
08/12/2024Buy Now543.78%Benchmark
Bruce Jackson42%
$15 → $15ReiteratesBuy → BuyGet Alert
07/15/2024Buy Now372.1%BTIG
Ryan Zimmerman72%
$8 → $11MaintainsBuyGet Alert
07/02/2024Buy Now200.43%Cantor Fitzgerald
Kristen Kluska70%
$7 → $7ReiteratesOverweight → OverweightGet Alert
07/02/2024Buy Now543.78%Benchmark
Bruce Jackson42%
$15 → $15ReiteratesBuy → BuyGet Alert
05/24/2024Buy Now543.78%Benchmark
Bruce Jackson42%
$15 → $15ReiteratesBuy → BuyGet Alert
05/13/2024Buy Now543.78%Benchmark
Bruce Jackson42%
$15 → $15ReiteratesBuy → BuyGet Alert
04/01/2024Buy Now200.43%Cantor Fitzgerald
Kristen Kluska70%
$7 → $7ReiteratesOverweight → OverweightGet Alert
03/26/2024Buy Now71.67%Piper Sandler
Allison Bratzel65%
$4 → $4MaintainsNeutralGet Alert
03/25/2024Buy Now543.78%Benchmark
Bruce Jackson42%
$15 → $15ReiteratesBuy → BuyGet Alert
03/08/2024Buy Now71.67%Piper Sandler
Allison Bratzel65%
$3 → $4MaintainsNeutralGet Alert
12/27/2023Buy Now543.78%Benchmark
Bruce Jackson42%
$16 → $15MaintainsBuyGet Alert
12/11/2023Buy Now157.51%HC Wainwright & Co.
Vernon Bernardino52%
→ $6Initiates → BuyGet Alert
11/10/2023Buy Now28.76%Piper Sandler
Matt O'Brien51%
$3.5 → $3MaintainsNeutralGet Alert
09/21/2023Buy Now200.43%Cantor Fitzgerald
Kristen Kluska70%
→ $7ReiteratesOverweight → OverweightGet Alert
08/31/2023Buy Now157.51%Cantor Fitzgerald
Kristen Kluska70%
→ $6ReiteratesOverweight → OverweightGet Alert
08/24/2023Buy Now157.51%Cantor Fitzgerald
Kristen Kluska70%
→ $6ReiteratesOverweight → OverweightGet Alert
08/15/2023Buy Now586.7%Benchmark
Bruce Jackson42%
→ $16ReiteratesBuy → BuyGet Alert
06/22/2023Buy Now157.51%Cantor Fitzgerald
Kristen Kluska70%
→ $6Initiates → OverweightGet Alert
06/12/2023Buy Now586.7%Benchmark
Bruce Jackson42%
→ $16ReiteratesBuy → BuyGet Alert
03/27/2023Buy Now586.7%Benchmark
Bruce Jackson42%
→ $16Reiterates → BuyGet Alert
07/18/2022Buy Now329.18%BTIG
Ryan Zimmerman72%
$12 → $10MaintainsBuyGet Alert

FAQ

Q

What is the target price for Humacyte (HUMA) stock?

A

The latest price target for Humacyte (NASDAQ:HUMA) was reported by HC Wainwright & Co. on March 12, 2025. The analyst firm set a price target for $15.00 expecting HUMA to rise to within 12 months (a possible 543.78% upside). 31 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Humacyte (HUMA)?

A

The latest analyst rating for Humacyte (NASDAQ:HUMA) was provided by HC Wainwright & Co., and Humacyte reiterated their buy rating.

Q

When was the last upgrade for Humacyte (HUMA)?

A

There is no last upgrade for Humacyte

Q

When was the last downgrade for Humacyte (HUMA)?

A

There is no last downgrade for Humacyte.

Q

When is the next analyst rating going to be posted or updated for Humacyte (HUMA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Humacyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Humacyte was filed on March 12, 2025 so you should expect the next rating to be made available sometime around March 12, 2026.

Q

Is the Analyst Rating Humacyte (HUMA) correct?

A

While ratings are subjective and will change, the latest Humacyte (HUMA) rating was a reiterated with a price target of $15.00 to $15.00. The current price Humacyte (HUMA) is trading at is $2.33, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch